These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19028276)

  • 1. mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
    Erben P; Horisberger K; Muessle B; Müller MC; Treschl A; Ernst T; Kähler G; Ströbel P; Wenz F; Kienle P; Post S; Hochhaus A; Willeke F; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1544-50. PubMed ID: 19028276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor volume reduction rate measured by magnetic resonance volumetry correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer.
    Yeo SG; Kim DY; Kim TH; Jung KH; Hong YS; Chang HJ; Park JW; Lim SB; Choi HS; Jeong SY
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):164-71. PubMed ID: 20004532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and significance of C-kit and platelet-derived growth factor receptor-beta (PDGFRbeta) in esophageal carcinoma].
    Zhang X; Rong TH; Zhang Y; Long H; Fu JH; Ling P; Zhang LJ; Yang MT; Zeng CG; Ma GW; Su XD; Li XD; Wang JY; Wen ZS; Zhao JM
    Ai Zheng; 2006 Jan; 25(1):92-5. PubMed ID: 16405759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
    Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
    Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
    Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
    Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.
    Kim JS; Kim JM; Li S; Yoon WH; Song KS; Kim KH; Yeo SG; Nam JS; Cho MJ
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):195-200. PubMed ID: 16839708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
    Weiss C; Arnold D; Dellas K; Liersch T; Hipp M; Fietkau R; Sauer R; Hinke A; Rödel C
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):472-8. PubMed ID: 20133081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.
    Vecchio FM; Valentini V; Minsky BD; Padula GD; Venkatraman ES; Balducci M; Miccichè F; Ricci R; Morganti AG; Gambacorta MA; Maurizi F; Coco C
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):752-60. PubMed ID: 15936556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
    Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
    Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
    Bertolini F; Chiara S; Bengala C; Antognoni P; Dealis C; Zironi S; Malavasi N; Scolaro T; Depenni R; Jovic G; Sonaglio C; Rossi A; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):466-72. PubMed ID: 19004567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.
    Welin S; Fjällskog ML; Saras J; Eriksson B; Janson ET
    Neuroendocrinology; 2006; 84(1):42-8. PubMed ID: 17047316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Carlomagno C; Pepe S; D'Armiento FP; D'Armiento M; Cannella L; De Stefano A; Crispo A; Giordano M; De Placido S
    Oncology; 2010; 78(5-6):369-75. PubMed ID: 20798559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Della Vittoria Scarpati G; Falcetta F; Carlomagno C; Ubezio P; Marchini S; De Stefano A; Singh VK; D'Incalci M; De Placido S; Pepe S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1113-9. PubMed ID: 22172905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy.
    Kobayashi H; Hashiguchi Y; Ueno H; Shinto E; Kajiwara Y; Mochizuki H
    Dis Colon Rectum; 2007 Sep; 50(9):1354-62. PubMed ID: 17308999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
    Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.